Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier in Clinical Oncology
- Vol. 6 (6) , 364-370
- https://doi.org/10.1016/s0936-6555(05)80188-8
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Mitomycin C as an Adjuvant Treatment to Resected Gastric CancerAnnals of Surgery, 1991
- Adenocarcinoma of the stomach: A review of 35 years and 1,710 casesWorld Journal of Surgery, 1990
- ADJUVANT CHEMOTHERAPY IN OPERABLE GASTRIC CANCERThe Lancet, 1989
- Pharmacokinetics of carboplatin after intraperitoneal administrationCancer Chemotherapy and Pharmacology, 1988
- Phase-III Clinical Trial of Adjuvant FAM2 (5-FU, Adriamycin and Mitomycin C) vs Control in Resectable Gastric Cancer: A Study of the EORTC Gastrointestinal Tract Cancer Cooperative GroupPublished by Springer Nature ,1988
- Adenocarcinoma of the stomach: Autopsy observations with therapeutic implications for the radiation oncologistRadiotherapy and Oncology, 1986
- Cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC gastrointestinal tract cancer cooperative groupEuropean Journal of Cancer and Clinical Oncology, 1985
- Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275)Cancer, 1985
- Cisplatin.An active drug in the treatment of disseminated gastric cancerCancer, 1984
- Gastric CarcinomaAnnals of Surgery, 1983